Lv5
1474 积分 2022-06-23 加入
Impact of skeletal complications on patients’ quality of life, mobility, and functional independence
3个月前
已完结
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial
3个月前
已完结
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
3个月前
已完结
Dynamic changes in folate receptor alpha scoring in ovarian surface epithelial carcinomas and treatment implications
3个月前
已关闭
The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma
3个月前
已完结
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
3个月前
已完结
P1.11.28 Nomogram and Effectiveness of Bone-Modifying Agents in Advanced Driver-Negative NSCLC: A Retrospective Real-World Study
3个月前
已关闭
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
4个月前
已完结
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
4个月前
已完结
P1.11.28 Nomogram and Effectiveness of Bone-Modifying Agents in Advanced Driver-Negative NSCLC: A Retrospective Real-World Study
4个月前
已关闭
皖公网安备34019202002308
